Clearside Biomedical Inc (CLSD)
1.34
+0.08
(+6.35%)
USD |
NASDAQ |
Apr 26, 16:00
1.30
-0.04
(-2.99%)
After-Hours: 20:00
Clearside Biomedical Debt to Equity Ratio: 0.00 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.1131 |
| September 30, 2020 | 0.122 |
| June 30, 2020 | 0.136 |
| March 31, 2020 | 0.4965 |
| Date | Value |
|---|---|
| December 31, 2019 | 0.4618 |
| September 30, 2019 | 1.041 |
| June 30, 2019 | 0.7828 |
| March 31, 2019 | 0.6237 |
| December 31, 2018 | 0.4223 |
| September 30, 2018 | 0.2248 |
| June 30, 2018 | 0.1477 |
| March 31, 2018 | 0.085 |
| December 31, 2017 | 0.374 |
| September 30, 2017 | 0.2142 |
| June 30, 2017 | 0.1435 |
| March 31, 2017 | 0.1145 |
| December 31, 2016 | 0.1059 |
| September 30, 2016 | 0.1596 |
| June 30, 2016 | 0.1239 |
| March 31, 2016 | 1.104 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Mar 2021
1.041
Maximum
Sep 2019
0.166
Average
--
Median
Mar 2021
Debt to Equity Ratio Benchmarks
| Cassava Sciences Inc | -- |
| Heron Therapeutics Inc | -5.114 |
| Actinium Pharmaceuticals Inc | 0.00 |
| Karyopharm Therapeutics Inc | -1.255 |
| Ocular Therapeutix Inc | 0.8222 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 34.02M |
| Total Liabilities (Quarterly) | 49.93M |
| Shareholders Equity (Quarterly) | -15.91M |
| Current Ratio | 4.421 |